FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386272424> ?p ?o ?g. }

• W4386272424 endingPage "827" @default.
• W4386272424 startingPage "818" @default.
• W4386272424 abstract "<b><i>Background:</i></b> The keloid treatment is still a thorny and complicated clinical problem, especially in multiple keloids induced by wound, severe burn, ethnic background or cultural behaviors, or unexplained skin healing. Mainstream treatments have limited efficacy in treating multiple keloids. As no oral treatment with painlessness and convenience is available, oral treatment strategies should be formulated. <b><i>Objectives:</i></b> This study aimed to investigate the efficacy and therapeutic mechanism of oral tofacitinib in keloid patients. <b><i>Methods:</i></b> We recruited the 7 patients with keloid scars and prescribed 5 mg of tofacitinib twice a day orally with a maximum follow-up of 12 weeks. The Patient and Observer Scar Assessment Scale (POSAS), the Vancouver scar scale (VSS), ANTERA 3D camera, and the DUB Skin Scanner 75 were used to assess the characteristics of the lesion. Immunohistochemistry was performed to evaluate collagen synthesis, proliferation, and relative molecular pathways. Moreover, the effects of tofacitinib were assessed on keloid fibroblast in vitro. <b><i>Results:</i></b> After 12 weeks of oral tofacitinib, significant improvement in POSAS, VSS, and Dermatology Life Quality Index (DLQI) scores was observed (<i>p</i> &lt; 0.05). The volume, lesion height, and dermis thickness of the keloid decreased (<i>p</i> &lt; 0.05). Moreover, significant decreases in the expression of collagen I, Ki67, p-STAT 3, and p-SMAD2 were observed after 12 weeks of administration. In vitro experiments suggested that tofacitinib treatment inhibits fibroblast proliferation and collagen I synthesis via suppression of STAT3 and SMAD2 pathway. <b><i>Conclusion:</i></b> Tofacitinib, a new candidate oral drug for keloid, could reduce keloid lesion volume by inhibiting collagen synthesis and inhibiting fibroblast proliferation, and alleviate itch and pain to obtain a better life quality." @default.
• W4386272424 created "2023-08-31" @default.
• W4386272424 creator A5017738335 @default.
• W4386272424 creator A5021564027 @default.
• W4386272424 creator A5021836870 @default.
• W4386272424 creator A5026494377 @default.
• W4386272424 creator A5037236993 @default.
• W4386272424 creator A5046297720 @default.
• W4386272424 creator A5080036448 @default.
• W4386272424 date "2023-01-01" @default.
• W4386272424 modified "2023-10-13" @default.
• W4386272424 title "An Open-Label, Uncontrolled, Single-Arm Clinical Trial of Tofacitinib, an Oral JAK1 and JAK3 Kinase Inhibitor, in Chinese Patients with Keloid" @default.
• W4386272424 cites W1981410961 @default.
• W4386272424 cites W2023136127 @default.
• W4386272424 cites W2028012252 @default.
• W4386272424 cites W2029529740 @default.
• W4386272424 cites W2032377131 @default.
• W4386272424 cites W2040002852 @default.
• W4386272424 cites W2041379039 @default.
• W4386272424 cites W2043900785 @default.
• W4386272424 cites W2046743471 @default.
• W4386272424 cites W2093668670 @default.
• W4386272424 cites W2108654280 @default.
• W4386272424 cites W2132173287 @default.
• W4386272424 cites W2184184250 @default.
• W4386272424 cites W2462475975 @default.
• W4386272424 cites W2510718951 @default.
• W4386272424 cites W2584430503 @default.
• W4386272424 cites W2593918601 @default.
• W4386272424 cites W2622107463 @default.
• W4386272424 cites W2752706812 @default.
• W4386272424 cites W2897348213 @default.
• W4386272424 cites W2900857121 @default.
• W4386272424 cites W2905097725 @default.
• W4386272424 cites W2922886236 @default.
• W4386272424 cites W2959501309 @default.
• W4386272424 cites W2971635939 @default.
• W4386272424 cites W2973138793 @default.
• W4386272424 cites W2978324492 @default.
• W4386272424 cites W2979754363 @default.
• W4386272424 cites W2990076552 @default.
• W4386272424 cites W3015696316 @default.
• W4386272424 cites W3022613687 @default.
• W4386272424 cites W3030413515 @default.
• W4386272424 cites W3030982632 @default.
• W4386272424 cites W3043618754 @default.
• W4386272424 cites W3045472422 @default.
• W4386272424 cites W3089974947 @default.
• W4386272424 cites W3096642903 @default.
• W4386272424 cites W3096828868 @default.
• W4386272424 cites W3097192879 @default.
• W4386272424 cites W3108729041 @default.
• W4386272424 cites W3115923263 @default.
• W4386272424 cites W4237769345 @default.
• W4386272424 cites W4252149492 @default.
• W4386272424 cites W4379466309 @default.
• W4386272424 doi "https://doi.org/10.1159/000532064" @default.
• W4386272424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37643592" @default.
• W4386272424 hasPublicationYear "2023" @default.
• W4386272424 type Work @default.
• W4386272424 citedByCount "0" @default.
• W4386272424 crossrefType "journal-article" @default.
• W4386272424 hasAuthorship W4386272424A5017738335 @default.
• W4386272424 hasAuthorship W4386272424A5021564027 @default.
• W4386272424 hasAuthorship W4386272424A5021836870 @default.
• W4386272424 hasAuthorship W4386272424A5026494377 @default.
• W4386272424 hasAuthorship W4386272424A5037236993 @default.
• W4386272424 hasAuthorship W4386272424A5046297720 @default.
• W4386272424 hasAuthorship W4386272424A5080036448 @default.
• W4386272424 hasConcept C126322002 @default.
• W4386272424 hasConcept C141071460 @default.
• W4386272424 hasConcept C16005928 @default.
• W4386272424 hasConcept C2776233030 @default.
• W4386272424 hasConcept C2777538232 @default.
• W4386272424 hasConcept C2777575956 @default.
• W4386272424 hasConcept C2777642821 @default.
• W4386272424 hasConcept C2778886723 @default.
• W4386272424 hasConcept C71924100 @default.
• W4386272424 hasConcept C90924648 @default.
• W4386272424 hasConcept C98274493 @default.
• W4386272424 hasConceptScore W4386272424C126322002 @default.
• W4386272424 hasConceptScore W4386272424C141071460 @default.
• W4386272424 hasConceptScore W4386272424C16005928 @default.
• W4386272424 hasConceptScore W4386272424C2776233030 @default.
• W4386272424 hasConceptScore W4386272424C2777538232 @default.
• W4386272424 hasConceptScore W4386272424C2777575956 @default.
• W4386272424 hasConceptScore W4386272424C2777642821 @default.
• W4386272424 hasConceptScore W4386272424C2778886723 @default.
• W4386272424 hasConceptScore W4386272424C71924100 @default.
• W4386272424 hasConceptScore W4386272424C90924648 @default.
• W4386272424 hasConceptScore W4386272424C98274493 @default.
• W4386272424 hasIssue "5" @default.
• W4386272424 hasLocation W43862724241 @default.
• W4386272424 hasLocation W43862724242 @default.
• W4386272424 hasOpenAccess W4386272424 @default.
• W4386272424 hasPrimaryLocation W43862724241 @default.
• W4386272424 hasRelatedWork W1545824045 @default.
• W4386272424 hasRelatedWork W2113082323 @default.

• next